Manufacturer of Controlled Substances; Notice of Registration, 44358-44359 [2011-18750]
Download as PDF
<![CDATA[
44358
Federal Register / Vol. 76, No. 142 / Monday, July 25, 2011 / Notices
the applicant can meet the applicable
performance standards for the special
type of mining activity.
Bureau Form Number: None.
Frequency of Collection: Once.
Description of Respondents:
Applicants for coalmine permits and
State Regulatory Authorities.
Total Annual Responses: 195 permit
applicants and 192 State regulatory
authorities.
Total Annual Burden Hours: 24,442.
Total Annual Non-Wage Costs: $0.
Dated: July 13, 2011.
Stephen M. Sheffield,
Acting Chief, Division of Regulatory Support.
[FR Doc. 2011–18214 Filed 7–22–11; 8:45 am]
BILLING CODE 4310–05–M
INTERNATIONAL TRADE
COMMISSION
[USITC SE–11–020]
Government in the Sunshine Act
Meeting Notice
United
States International Trade Commission.
TIME AND DATE: July 27, 2011 at 11 a.m.
PLACE: Room 101, 500 E Street, SW.,
Washington, DC 20436. Telephone:
(202) 205–2000.
STATUS: Open to the public.
MATTERS TO BE CONSIDERED:
1. Agendas for future meetings: none.
2. Minutes
3. Ratification List
4. Vote in Inv. Nos. 731–TA–457–A–
D (Third Review)(Heavy Forged Hand
Tools from China). The Commission is
currently scheduled to transmit its
determinations and Commissioners’
opinions to the Secretary of Commerce
on or before August 10, 2011.
5. Outstanding action jackets: none.
In accordance with Commission
policy, subject matter listed above, not
disposed of at the scheduled meeting,
may be carried over to the agenda of the
following meeting.
AGENCY HOLDING THE MEETING:
By order of the Commission.
Issued: July 20, 2011.
William R. Bishop,
Hearings and Meetings Coordinator.
jlentini on DSK4TPTVN1PROD with NOTICES
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Notice of Lodging Proposed Consent
Decree
VerDate Mar<15>2010
16:15 Jul 22, 2011
Jkt 223001
Cherie L. Rogers,
Assistant Section Chief, Environmental
Defense Section, Environment & Natural
Resources Division.
[FR Doc. 2011–18659 Filed 7–22–11; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
[FR Doc. 2011–18859 Filed 7–21–11; 11:15 am]
In accordance with Departmental
Policy, 28 CFR 50.7, notice is hereby
given that a proposed Consent Decree in
United States v. Northstar Materials,
Inc. (d/b/a Knife River Materials) &
Knife River Corporation, Civil No. 0:11–
cv–01950–RHK–LIB, was lodged with
the United States District Court for the
District of Minnesota on July 18, 2011.
This proposed Consent Decree
concerns a complaint filed by the
United States against Defendants,
pursuant to Sections 301, 309 and 404
of the Clean Water Act, 33 U.S.C. 1311,
1319 and 1344 to obtain injunctive relief
and impose civil penalties against the
Defendants for violating the Clean Water
Act by discharging fill material into
waters of the United States. The
proposed Consent Decree resolves these
allegations by requiring the Defendants
to restore the impacted areas and/or
perform mitigation and to pay a civil
penalty. The Department of Justice will
accept written comments relating to this
proposed Consent Decree for thirty (30)
days from the date of publication of this
Notice. Please address comments to Ana
H. Voss, Assistant United States
Attorney, United States Attorney’s
Office, District of Minnesota, 600 United
States Courthouse, 300 South Fourth
Street, Minneapolis, Minnesota 55415
and refer to U.S.A.O. file number
2010v00217 and DJ #90–5–1–1–18739.
The proposed Consent Decree may be
examined at the Clerk’s Office of the
United States District Court for the
District of Minnesota, 300 South Fourth
Street, Suite 202, Minneapolis,
Minnesota 55415. In addition, the
proposed Consent Decree may be
viewed at https://www.usdoj.gov/enrd/
Consent_Decrees.html.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on June 16, 2011,
American Radiolabeled Chemicals, Inc.,
101 Arc Drive, St. Louis, Missouri
63146, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Carfentanil (9743), a
basic class of controlled substance listed
in schedule II.
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
The company plans to manufacture
small quantities of the listed controlled
substance as radiolabeled compounds
for biochemical research.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than September 23, 2011.
Dated: July 19, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–18752 Filed 7–22–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated April 13, 2011, and
published in the Federal Register on
April 20, 2011, 76 FR 22146, Noramco,
Inc., 500 Swedes Landing Road,
Wilmington, Delaware 19801–4485,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Amphetamine (1100) ....................
Phenylacetone (8501) ..................
Schedule
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Noramco, Inc. to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time.
DEA has investigated Noramco, Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
E:\FR\FM\25JYN1.SGM
25JYN1
Federal Register / Vol. 76, No. 142 / Monday, July 25, 2011 / Notices
Therefore, pursuant to 21 U.S.C.
§ 823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: July 19, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–18750 Filed 7–22–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
jlentini on DSK4TPTVN1PROD with NOTICES
By Notice dated April 11, 2011, and
published in the Federal Register on
April 19, 2011, 76 FR 21916,
Mallinckrodt Inc., 3600 North Second
Street, St. Louis, Missouri 63147, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
4–Anilino-N-Phenethyl-4-Piperidine
(8333), a basic class of controlled
substance listed in schedule II.
The company plans to use this
controlled substance in the manufacture
of another controlled substance.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Mallinckrodt, Inc., to manufacture the
listed basic class of controlled substance
is consistent with the public interest at
this time. DEA has investigated
Mallinckrodt, Inc., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: July 19, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–18751 Filed 7–22–11; 8:45 am]
BILLING CODE 4410–09–P
VerDate Mar<15>2010
16:15 Jul 22, 2011
Jkt 223001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 09–51]
Paul Weir Battershell, N.P.;
Suspension Of Registration
On May 8, 2009, the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, issued an Order to
Show Cause to Paul Weir Battershell,
N.P. (‘‘Respondent’’), of Caldwell and
Meridian, Idaho. The Show Cause Order
proposed the revocation of
Respondent’s DEA Certificates of
Registration MB1090670 (for his
Caldwell registered location) and
MB1294711 (for his Meridian registered
location), and the denial of any pending
applications to renew or modify either
registration, on the ground that his
‘‘continued registration is inconsistent
with the public interest, as that term is
defined in 21 U.S.C. § 823(f).’’ ALJ Ex.
1, at 1.
The Show Cause Order specifically
alleged that from ‘‘July 2005 through at
least August 2006,’’ Respondent
‘‘prescribed and dispensed Human
Growth Hormone and controlled
substances, including anabolic steroids,
to individuals for no legitimate medical
purpose and outside the course of
professional practice’’ in violation of 21
U.S.C. §§ 333(e) and 841(a)(1), as well as
21 CFR 1306.04(a). Id. at 1.
The Order further alleged that from
September 2005 through August 2006,
Respondent ‘‘failed to maintain proper
security over [his] controlled substances
by not maintaining a proper key control
system, failing to maintain adequate
supervision over fellow employees who
handle[d] [his] controlled substances
and failing to monitor the distribution of
[his] controlled substances in violation
of 21 CFR 1301.71.’’ Id. The Order also
alleged that ‘‘[i]n August 2005,’’
Respondent ‘‘failed to record the
transfer of another practitioner’s
controlled substances into [his]
inventory, when that practitioner left
the clinic where [Respondent] was
employed,’’ id. at 2 (citing 21 U.S.C.
§ 827(a)(3) and 21 CFR 1304.21); that
‘‘[i]n November and December 2005,’’
he ‘‘failed to keep records of controlled
substances [he] received, specifically
Phentermine 30 mg’’; and that ‘‘during
calendar year 2005,’’ Respondent further
‘‘failed to properly record the date on
[his] dispensing records.’’ Id. (citing 21
U.S.C. § 827(a)(3) and 21 CFR 1304.21 &
1304.22).
Finally, the Show Cause Order alleged
that ‘‘[d]uring 2005 and 2006,’’
Respondent ‘‘accepted controlled
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
44359
substances from non-DEA registered
sources (patients) in violation of 21
U.S.C. § 844(a) and redistributed those
illicitly obtained controlled substances
to other patients in violation of 21
U.S.C. § 841(a)(1).’’ Id.
On June 5, 2009, counsel for
Respondent timely requested a hearing,
and the matter was placed on the docket
of the Agency’s Administrative Law
Judges (ALJs). ALJ Ex. 2. Following prehearing procedures, an ALJ conducted a
hearing in Boise, Idaho on December 1–
2, 2009. At the hearing, both parties
called witnesses to testify and
introduced documentary evidence.
Following the hearing, both parties
submitted post-hearing briefs.
On April 9, 2010, the ALJ issued her
Recommended Decision (also ALJ).
Therein, the ALJ, after considering the
five public interest factors, see 21 U.S.C.
§ 823(f), recommended that Respondent
be granted a restricted registration and
be admonished.
As to the first factor—the
recommendation of the appropriate state
licensing board—the ALJ found that
while the Idaho Board of Pharmacy
(Board) had previously placed
Respondent on probation, there was ‘‘no
pending action[] against’’ him and ‘‘the
Board has made no recommendations
with regards to his registration.’’ ALJ at
34. As to the second factor—
Respondent’s experience in dispensing
controlled substances—the ALJ found
that ‘‘Respondent’s actions as well as
his own statements suggest that at the
time of these infractions in 2006,
[Respondent] was inexperienced, or at
least unaware of numerous regulations
relating to the security and inventory
requirements for controlled substances
under the [Controlled Substances Act].’’
Id. at 34–35. She further found that
while Respondent claimed that he had
‘‘sought guidance but did not receive it
* * * in some instances, when [he] did
receive such guidance, he was still
unable to follow it.’’ Id. at 35. The ALJ
thus concluded that ‘‘the record
demonstrates that [Respondent’s] past
practices demonstrate a lack of
knowledgeable experience in handling
controlled substances.’’ Id.
As to factor three—Respondent’s
conviction record for offenses related to
the distribution or dispensing of
controlled substances—the ALJ found
that the ‘‘record contains no evidence of
any convictions related to the handling
of controlled substances.’’ Id. The ALJ
thus concluded that ‘‘this factor does
not fall in favor of revocation.’’ Id.
With respect to the fourth factor—
Respondent’s compliance with
applicable State, Federal or local laws
related to controlled substances—the
E:\FR\FM\25JYN1.SGM
25JYN1
]]>Agencies
[Federal Register Volume 76, Number 142 (Monday, July 25, 2011)]
[Notices]
[Pages 44358-44359]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-18750]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated April 13, 2011, and published in the Federal
Register on April 20, 2011, 76 FR 22146, Noramco, Inc., 500 Swedes
Landing Road, Wilmington, Delaware 19801-4485, made application by
letter to the Drug Enforcement Administration (DEA) to be registered as
a bulk manufacturer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Amphetamine (1100)......................... II
Phenylacetone (8501)....................... II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Noramco, Inc. to manufacture the listed basic classes of controlled
substances is consistent with the public interest at this time.
DEA has investigated Noramco, Inc. to ensure that the company's
registration is consistent with the public interest. The investigation
has included inspection and testing of the company's physical security
systems, verification of the company's compliance with state and local
laws, and a review of the company's background and history.
[[Page 44359]]
Therefore, pursuant to 21 U.S.C. Sec. 823(a), and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic classes of controlled substances listed.
Dated: July 19, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-18750 Filed 7-22-11; 8:45 am]
BILLING CODE 4410-09-P
